NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 2017
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
4
Data completeness
5/8 — Partial
VYZULTA (latanoprostene bunod) by Bausch + Lomb. Approved for ocular hypertension, open-angle glaucoma, glaucoma. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYZULTA (latanoprostene bunod) is an ophthalmic solution approved by the FDA on November 2, 2017, for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a novel prodrug that combines a prostaglandin F analog with a nitric oxide-donating moiety, providing a dual mechanism of action to reduce intraocular pressure. The product represents an innovative approach to glaucoma therapy by leveraging both prostaglandin and nitric oxide pathways to enhance ocular hypotensive efficacy.
$0.1BPart D
2.8 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on VYZULTA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.